{"pmid":32345702,"title":"Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.","text":["Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.","BACKGROUND: Some patients with COVID-19 pneumonia also present with kidney injury, and autopsy findings of patients who died from the illness sometimes show renal damage. However, little is known about the clinical characteristics of kidney-related complications, including hematuria, proteinuria, and AKI. METHODS: In this retrospective, single-center study in China, we analyzed data from electronic medical records of 333 hospitalized patients with COVID-19 pneumonia, including information about clinical, laboratory, radiologic, and other characteristics, as well as information about renal outcomes. RESULTS: We found that 251 of the 333 patients (75.4%) had abnormal urine dipstick tests or AKI. Of 198 patients with renal involvement for the median duration of 12 days, 118 (59.6%) experienced remission of pneumonia during this period, and 111 of 162 (68.5%) patients experienced remission of proteinuria. Among 35 patients who developed AKI (with AKI identified by criteria expanded somewhat beyond the 2012 Kidney Disease: Improving Global Outcomes definition), 16 (45.7%) experienced complete recovery of kidney function. We suspect that most AKI cases were intrinsic AKI. Patients with renal involvement had higher overall mortality compared with those without renal involvement (28 of 251 [11.2%] versus one of 82 [1.2%], respectively). Stepwise multivariate binary logistic regression analyses showed that severity of pneumonia was the risk factor most commonly associated with lower odds of proteinuric or hematuric remission and recovery from AKI. CONCLUSIONS: Renal abnormalities occurred in the majority of patients with COVID-19 pneumonia. Although proteinuria, hematuria, and AKI often resolved in such patients within 3 weeks after the onset of symptoms, renal complications in COVID-19 were associated with higher mortality.","J Am Soc Nephrol","Pei, Guangchang","Zhang, Zhiguo","Peng, Jing","Liu, Liu","Zhang, Chunxiu","Yu, Chong","Ma, Zufu","Huang, Yi","Liu, Wei","Yao, Ying","Zeng, Rui","Xu, Gang","32345702"],"abstract":["BACKGROUND: Some patients with COVID-19 pneumonia also present with kidney injury, and autopsy findings of patients who died from the illness sometimes show renal damage. However, little is known about the clinical characteristics of kidney-related complications, including hematuria, proteinuria, and AKI. METHODS: In this retrospective, single-center study in China, we analyzed data from electronic medical records of 333 hospitalized patients with COVID-19 pneumonia, including information about clinical, laboratory, radiologic, and other characteristics, as well as information about renal outcomes. RESULTS: We found that 251 of the 333 patients (75.4%) had abnormal urine dipstick tests or AKI. Of 198 patients with renal involvement for the median duration of 12 days, 118 (59.6%) experienced remission of pneumonia during this period, and 111 of 162 (68.5%) patients experienced remission of proteinuria. Among 35 patients who developed AKI (with AKI identified by criteria expanded somewhat beyond the 2012 Kidney Disease: Improving Global Outcomes definition), 16 (45.7%) experienced complete recovery of kidney function. We suspect that most AKI cases were intrinsic AKI. Patients with renal involvement had higher overall mortality compared with those without renal involvement (28 of 251 [11.2%] versus one of 82 [1.2%], respectively). Stepwise multivariate binary logistic regression analyses showed that severity of pneumonia was the risk factor most commonly associated with lower odds of proteinuric or hematuric remission and recovery from AKI. CONCLUSIONS: Renal abnormalities occurred in the majority of patients with COVID-19 pneumonia. Although proteinuria, hematuria, and AKI often resolved in such patients within 3 weeks after the onset of symptoms, renal complications in COVID-19 were associated with higher mortality."],"journal":"J Am Soc Nephrol","authors":["Pei, Guangchang","Zhang, Zhiguo","Peng, Jing","Liu, Liu","Zhang, Chunxiu","Yu, Chong","Ma, Zufu","Huang, Yi","Liu, Wei","Yao, Ying","Zeng, Rui","Xu, Gang"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345702","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1681/ASN.2020030276","keywords":["acute kidney failure","covid-19","hematuria","pneumonia","proteinuria"],"locations":["hematuria","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495434883072,"score":9.490897,"similar":[{"pmid":32416769,"title":"Management of acute kidney injury in patients with COVID-19.","text":["Management of acute kidney injury in patients with COVID-19.","The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management.","Lancet Respir Med","Ronco, Claudio","Reis, Thiago","Husain-Syed, Faeq","32416769"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management."],"journal":"Lancet Respir Med","authors":["Ronco, Claudio","Reis, Thiago","Husain-Syed, Faeq"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416769","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/S2213-2600(20)30229-0","topics":["Treatment"],"weight":1,"_version_":1667058206819483648,"score":359.75128},{"pmid":32247631,"pmcid":"PMC7110296","title":"Kidney disease is associated with in-hospital death of patients with COVID-19.","text":["Kidney disease is associated with in-hospital death of patients with COVID-19.","In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m(2) were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+ approximately 3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+ approximately 3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19.","Kidney Int","Cheng, Yichun","Luo, Ran","Wang, Kun","Zhang, Meng","Wang, Zhixiang","Dong, Lei","Li, Junhua","Yao, Ying","Ge, Shuwang","Xu, Gang","32247631"],"abstract":["In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m(2) were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+ approximately 3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+ approximately 3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19."],"journal":"Kidney Int","authors":["Cheng, Yichun","Luo, Ran","Wang, Kun","Zhang, Meng","Wang, Zhixiang","Dong, Lei","Li, Junhua","Yao, Ying","Ge, Shuwang","Xu, Gang"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247631","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.kint.2020.03.005","keywords":["covid-19","acute kidney injury","in-hospital death","kidney disease","pneumonia"],"locations":["Wuhan","Hubei","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nitrogen","Creatinine","Urea"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492010233856,"score":354.88187},{"pmid":32416116,"title":"ACUTE KIDNEY INJURY IN PATIENTS HOSPITALIZED WITH COVID-19.","text":["ACUTE KIDNEY INJURY IN PATIENTS HOSPITALIZED WITH COVID-19.","The rate of acute kidney injury (AKI) associated with patients hospitalized with Covid-19, and associated outcomes are not well understood. This study describes the presentation, risk factors and outcomes of AKI in patients hospitalized with Covid-19. We reviewed the health records for all patients hospitalized with Covid-19 between March 1, and April 5, 2020, at 13 academic and community hospitals in metropolitan New York. Patients younger than 18 years of age, with end stage kidney disease or with a kidney transplant were excluded. AKI was defined according to KDIGO criteria. Of 5,449 patients admitted with Covid-19, AKI developed in 1,993 (36.6%). The peak stages of AKI were stage 1 in 46.5%, stage 2 in 22.4% and stage 3 in 31.1%. Of these, 14.3% required renal replacement therapy (RRT). AKI was primarily seen in Covid-19 patients with respiratory failure, with 89.7% of patients on mechanical ventilation developing AKI compared to 21.7% of non-ventilated patients. 276/285 (96.8%) of patients requiring RRT were on ventilators. Of patients who required ventilation and developed AKI, 52.2% had the onset of AKI within 24 hours of intubation. Risk factors for AKI included older age, diabetes mellitus, cardiovascular disease, black race, hypertension and need for ventilation and vasopressor medications. Among patients with AKI, 694 died (35%), 519 (26%) were discharged and 780 (39%) were still hospitalized. AKI occurs frequently among patients with Covid-19 disease. It occurs early and in temporal association with respiratory failure and is associated with a poor prognosis.","Kidney Int","Hirsch, Jamie S","Ng, Jia H","Ross, Daniel W","Sharma, Purva","Shah, Hitesh H","Barnett, Richard L","Hazzan, Azzour D","Fishbane, Steven","Jhaveri, Kenar D","32416116"],"abstract":["The rate of acute kidney injury (AKI) associated with patients hospitalized with Covid-19, and associated outcomes are not well understood. This study describes the presentation, risk factors and outcomes of AKI in patients hospitalized with Covid-19. We reviewed the health records for all patients hospitalized with Covid-19 between March 1, and April 5, 2020, at 13 academic and community hospitals in metropolitan New York. Patients younger than 18 years of age, with end stage kidney disease or with a kidney transplant were excluded. AKI was defined according to KDIGO criteria. Of 5,449 patients admitted with Covid-19, AKI developed in 1,993 (36.6%). The peak stages of AKI were stage 1 in 46.5%, stage 2 in 22.4% and stage 3 in 31.1%. Of these, 14.3% required renal replacement therapy (RRT). AKI was primarily seen in Covid-19 patients with respiratory failure, with 89.7% of patients on mechanical ventilation developing AKI compared to 21.7% of non-ventilated patients. 276/285 (96.8%) of patients requiring RRT were on ventilators. Of patients who required ventilation and developed AKI, 52.2% had the onset of AKI within 24 hours of intubation. Risk factors for AKI included older age, diabetes mellitus, cardiovascular disease, black race, hypertension and need for ventilation and vasopressor medications. Among patients with AKI, 694 died (35%), 519 (26%) were discharged and 780 (39%) were still hospitalized. AKI occurs frequently among patients with Covid-19 disease. It occurs early and in temporal association with respiratory failure and is associated with a poor prognosis."],"journal":"Kidney Int","authors":["Hirsch, Jamie S","Ng, Jia H","Ross, Daniel W","Sharma, Purva","Shah, Hitesh H","Barnett, Richard L","Hazzan, Azzour D","Fishbane, Steven","Jhaveri, Kenar D"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416116","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.kint.2020.05.006","keywords":["aki","covid-19","crrt","dialysis","renal failure"],"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666994545963827200,"score":344.7424},{"pmid":32412303,"title":"Is the kidney a target of SARS-CoV-2?","text":["Is the kidney a target of SARS-CoV-2?","The new disease produced by the Severe Acute Respiratory Syndrome - coronavirus 2 (SARS-CoV-2) represents a major pandemic event nowadays. Since its origin in China in December 2019, there is compelling evidence that novel SARS-CoV-2 is a highly transmissible virus, and it is associated to a broad clinical spectrum going from subclinical presentation to severe respiratory distress and multi-organ failure. Like other coronaviruses, SARS-CoV-2 recognizes the human Angiotensin Converting Enzyme 2 (hACE2) as a cellular receptor that allows it to infect different host cells, and likely disrupts the renin-angiotensin-aldosterone system (RAAS) homeostasis. Particularly, it has been reported a considerable incidence of many renal abnormalities associated to COVID-19, including proteinuria, hematuria and acute kidney injury (AKI). Moreover, it has been recently demonstrated that SARS-CoV-2 can infect podocytes and tubular epithelial cells, which could contribute to the development of the aforementioned renal abnormalities. In this review, we discuss the biological aspects of the SARS-CoV-2 infection, how understanding current knowledge about SARS-CoV-2 infection may partly explain the involvement of the kidneys in the pathophysiology of COVID-19, and what questions arise and remain to be explored.","Am J Physiol Renal Physiol","Martinez-Rojas, Miguel A","Vega-Vega, Olynka","Bobadilla, Norma A","32412303"],"abstract":["The new disease produced by the Severe Acute Respiratory Syndrome - coronavirus 2 (SARS-CoV-2) represents a major pandemic event nowadays. Since its origin in China in December 2019, there is compelling evidence that novel SARS-CoV-2 is a highly transmissible virus, and it is associated to a broad clinical spectrum going from subclinical presentation to severe respiratory distress and multi-organ failure. Like other coronaviruses, SARS-CoV-2 recognizes the human Angiotensin Converting Enzyme 2 (hACE2) as a cellular receptor that allows it to infect different host cells, and likely disrupts the renin-angiotensin-aldosterone system (RAAS) homeostasis. Particularly, it has been reported a considerable incidence of many renal abnormalities associated to COVID-19, including proteinuria, hematuria and acute kidney injury (AKI). Moreover, it has been recently demonstrated that SARS-CoV-2 can infect podocytes and tubular epithelial cells, which could contribute to the development of the aforementioned renal abnormalities. In this review, we discuss the biological aspects of the SARS-CoV-2 infection, how understanding current knowledge about SARS-CoV-2 infection may partly explain the involvement of the kidneys in the pathophysiology of COVID-19, and what questions arise and remain to be explored."],"journal":"Am J Physiol Renal Physiol","authors":["Martinez-Rojas, Miguel A","Vega-Vega, Olynka","Bobadilla, Norma A"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412303","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1152/ajprenal.00160.2020","keywords":["ace2","covid-19","raas","acute kidney injury","proteinuria"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Aldosterone"],"topics":["Mechanism"],"weight":1,"_version_":1666989866117758976,"score":343.63187},{"pmid":32229732,"pmcid":"PMC7179524","title":"Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China.","text":["Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China.","BACKGROUND: Whether the patients with coronavirus disease 19 (COVID-19) infected by severe acute respiratory syndrome (SARS)-CoV-2 would commonly develop acute kidney injury (AKI) is an important issue worthy of clinical attention. This study aimed to explore the effects of SARS-CoV-2 infection on renal function through analyzing the clinical data of 116 hospitalized COVID-19-confirmed patients. METHODS: One hundred sixteen COVID-19-confirmed patients enrolled in this study were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University from January 14 to February 13, 2020. The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs, laboratory test results, chest computer tomography scans, and treatment measures. SARS-CoV-2 RNA in 53 urine sediments of enrolled patients was detected by real-time reverse transcription-polymerase chain reaction. RESULTS: Twelve (10.8%) patients showed mild increase of blood urea nitrogen or creatinine (<26 mumol/L within 48 h), and 8 (7.2%) patients showed trace or 1+ albuminuria in 111 COVID-19-confirmed patients without chronic kidney disease (CKD). All these patients did not meet the diagnostic criteria of AKI. In addition, 5 patients with CKD who were undergone regular continuous renal replacement therapy (CRRT) before admission were confirmed infection of SARS-CoV-2 and diagnosed as COVID-19. In addition to therapy for COVID-19, CRRT was also applied 3 times weekly during hospitalization for these 5 patients with CKD. In the course of treatment, the renal function indicators showed stable state in all 5 patients with CKD, without exacerbation of CKD, and pulmonary inflammation was gradually absorbed. All 5 patients with CKD were survived. Moreover, SARS-CoV-2 RNA in urine sediments was positive only in 3 patients from 48 cases without CKD, and 1 patient had a positive for SARS-CoV-2 open reading frame 1ab from 5 cases with CKD. CONCLUSION: AKI was uncommon in COVID-19. SARS-CoV-2 infection does not result in AKI, or aggravate CKD in the COVID-19 patients.","Am J Nephrol","Wang, Luwen","Li, Xun","Chen, Hui","Yan, Shaonan","Li, Dong","Li, Yan","Gong, Zuojiong","32229732"],"abstract":["BACKGROUND: Whether the patients with coronavirus disease 19 (COVID-19) infected by severe acute respiratory syndrome (SARS)-CoV-2 would commonly develop acute kidney injury (AKI) is an important issue worthy of clinical attention. This study aimed to explore the effects of SARS-CoV-2 infection on renal function through analyzing the clinical data of 116 hospitalized COVID-19-confirmed patients. METHODS: One hundred sixteen COVID-19-confirmed patients enrolled in this study were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University from January 14 to February 13, 2020. The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs, laboratory test results, chest computer tomography scans, and treatment measures. SARS-CoV-2 RNA in 53 urine sediments of enrolled patients was detected by real-time reverse transcription-polymerase chain reaction. RESULTS: Twelve (10.8%) patients showed mild increase of blood urea nitrogen or creatinine (<26 mumol/L within 48 h), and 8 (7.2%) patients showed trace or 1+ albuminuria in 111 COVID-19-confirmed patients without chronic kidney disease (CKD). All these patients did not meet the diagnostic criteria of AKI. In addition, 5 patients with CKD who were undergone regular continuous renal replacement therapy (CRRT) before admission were confirmed infection of SARS-CoV-2 and diagnosed as COVID-19. In addition to therapy for COVID-19, CRRT was also applied 3 times weekly during hospitalization for these 5 patients with CKD. In the course of treatment, the renal function indicators showed stable state in all 5 patients with CKD, without exacerbation of CKD, and pulmonary inflammation was gradually absorbed. All 5 patients with CKD were survived. Moreover, SARS-CoV-2 RNA in urine sediments was positive only in 3 patients from 48 cases without CKD, and 1 patient had a positive for SARS-CoV-2 open reading frame 1ab from 5 cases with CKD. CONCLUSION: AKI was uncommon in COVID-19. SARS-CoV-2 infection does not result in AKI, or aggravate CKD in the COVID-19 patients."],"journal":"Am J Nephrol","authors":["Wang, Luwen","Li, Xun","Chen, Hui","Yan, Shaonan","Li, Dong","Li, Yan","Gong, Zuojiong"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32229732","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1159/000507471","keywords":["acute kidney injury","chronic kidney disease","continuous renal replacement therapy","coronavirus disease 19","severe acute respiratory syndrome-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nitrogen","Creatinine"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138492185346048,"score":333.37302}]}